;-)I agree. I recently saw an old veteran Alzheimers researcher get totally tongue tied over Roch's Gantenerumab. Roche have done what I bet they think is a very clever move. Several months back they started a phase 2 with that drug in prodormal(pre Alzheimer's) They got it all set up and running then pronounced they were converting it into a pivitol for approval. It will take about 5 years. In one swoop they had stolen the lead from JNJ/PFE/ELN if Bapi failed. They may have been just too clever because Bapi failed so badly I dont think anyone is going after prodormal with it. Also I dont think a MAB will work against prodormal either. Prana's phase 2 has some prodormals in it and indications are that PBT2 works fast in prodormal where little neuron damage is present. This 12 month IMAGINE trial now running should tell the story. They have shown efficacy already against mild Alzheimer's patients, but the only work they have done so far in normal age related memory loss has been in an animal model, where youthful cognition levels were restored from day one in the study. Effect was almost immediate, and no changes were seen in young animals treated with the same drug, indicating the drug was engaging the aging effect in the brain. If JNJ bought into Prana's effort PBT2 would be a better name.